Plasma exchange therapy for familial chylomicronemia syndrome in infant: A case report

Medicine (Baltimore). 2022 Aug 12;101(32):e29689. doi: 10.1097/MD.0000000000029689.

Abstract

Introduction: Familial chylomicronemia syndrome (FCS) is a rare genetic disease. FCS usually manifests by the age of 10 years, and 25% of cases of FCS occur during infancy. Here we present a case of FCS in a male infant and summarize our experiences on the diagnosis and therapy of this case.

Patient concerns: A male infant aged 1 month and 8 days had recurrent hematochezia and hyperchylomicronemia.

Diagnosis: FCS based on symptoms and genetic test.

Interventions: Plasma exchange therapy.

Outcomes: His development was normal with a good spirit and satisfactory weight gain, and no hematochezia occurred again.

Conclusion: Genetic test is important for accurate diagnosis of FCS, and we identified a new mutation of lipoprotein lipase gene c.88C>A which conformed to autosomal recessive inheritance. Plasma exchange therapy can be applied to infants with FCS with low risk and good outcomes.

Publication types

  • Case Reports

MeSH terms

  • Genetic Testing
  • Humans
  • Hyperlipoproteinemia Type I* / genetics
  • Hyperlipoproteinemia Type I* / therapy
  • Infant
  • Male
  • Plasma Exchange
  • Plasmapheresis

Supplementary concepts

  • Familial hyperchylomicronemia syndrome